Group items tagged

The Royal Pharmaceutical Society (RPS) has called on employers, governments and NHS organisations to provide pharmacists with regular protected learning time (PLT) within working hours to develop their skills in clinical delivery, education, research and leadership. RPS workforce wellbeing survey showed an average 42 per cent of pharmacists were not given any PLT, a figure which rose to 55 per cent in community pharmacy. Most were unable to engage in professional development activities as part of their working day because of their responsibility to deliver frontline clinical services to patients. This means learning is often undertaken outside of working hours, increasing pressure on individuals and impacting their work/life balance. The survey showed that 48 per cent of respondents identified a lack of PLT as negatively affecting their mental health and wellbeing and that 88 per cent were at high risk of burnout. PLT improves the quality of patient care through professional practice and reflection, helping to develop insights, maintain and refine care standards and increase confidence. It facilitates continuous professional development (CPD), ensuring that skills and knowledge are up to date.

The country as a whole is facing uncertain and challenging times, and for our profession emerging from the second year of the pandemic, the pressures and stresses don't look to be easing up. It is undeniable that the wellbeing of those in our pharmacy family has suffered and many face emotional and psychological challenges in addition to immense workplace pressure. What do we know about the state of wellbeing within the profession? As the profession's independent charity, it is crucial that Pharmacist Support keeps abreast of the changing needs of the profession to enable us to meet the needs of those we are here to help. To do this, each year we collaborate with the Royal Pharmaceutical Society (RPS) to carry out an annual Workforce Wellbeing Survey. The last survey carried out was in the latter part of 2021 but nothing has changed since. And the results provided stark reading. Of the 1,014 responses received, many reported living with 'poor' or 'very poor' mental health and wellbeing. The survey results highlight a continued clear need for mental health and wellbeing support. Within the survey, it was identified that there is a very clear need for independent assistance, with many saying they feel unable to talk to their employers about their mental health issues. The need for our charity has never been clearer.

In a bid to bolster the educational experience for undergraduate pharmacy students across London, Kingston University has embarked on a groundbreaking project in collaboration with University College London and King's College London. This initiative, fueled by a substantial £1.5 million investment from National Health Services England (NHSE), aims to elevate the quality and consistency of pharmacy placements throughout the capital for new pharmacy entrants. The project is designed to address the evolving standards set forth by the General Pharmaceutical Council (GphC), ensuring that newly-trained pharmacists are well-prepared to meet the demands of their profession. By standardizing and expanding pharmacy placements, the three universities seek to provide students with a comprehensive and diverse range of "experiential learning opportunities".

The Integrated Care Systems (ICSs) provide an opportunity to break the silo mentality in the health and care sector, National Pharmacy Association (NPA) chair Andrew Lane told MPs. While giving evidence to the Health and Social Care Select Committee on 6 December about the effectiveness of ICSs, Lane also poured cold water on newspaper reports that community pharmacists will be drafted in to break the NHS strike, as he reiterated the call for a "properly costed and funded environment." "We've been in different silos historically and ICSs are an opportunity to pull all systems together for the benefit of patients," he told committee members. Lane pointed to dementia-trained pharmacy delivery drivers and the Discharge Medicines Service as instances where the influence of community pharmacy already stretches beyond primary care into hospitals and social care. "We've seen pharmacists prescribe and get UTIs off doctors' desks, so we are starting to release capacity [in the system] and we're on that clinical journey. We welcome that, but it has to be with the right level of funding," he added.

Campaigners have submitted an open letter to the Department of Health and Social Care (DHSC), urging the Minister for Primary Care and Public Health to freeze prescription charges to keep people with long-term conditions alive and well. The campaign is led by the Prescription Charges Coalition, which represents over 50 organisations, including Royal Pharmaceutical Society (RPS) and Pharmacists' Defence Association (PDA). Currently, the prescription charge is £9.65 per item, and campaigners have asked the government to freeze it for 2024 and 2025 as people living with long-term health conditions in England are "being forced to choose between heating, eating, and taking their vital medication on a daily basis." In 2023, a study conducted by the Prescription Charges Coalition revealed that almost 10 per cent of survey participants had skipped medication in the previous year due to the cost of prescriptions. This led to increased physical and mental health problems, as well as impacted the time they took off work. Laura Cockram, Chair of the Prescription Charges Coalition and Head of Campaigns at Parkinson's UK, expressed deep concern that a further rise in the charge this year will lead to people skipping or not taking the full dose of their medication, which will affect their health and put more pressure on the already under pressure NHS.

The Pharmacists' Defence Association (PDA) has made the its 'Education revision programme' accessible for new registrations who are preparing for the GPhC/PSNI November 2022 assessment. The programme offers a wide range of practice calculations questions, some mock exams, practical tips on revision, and an opportunity to chat to other PDA members who are preparing to sit the assessment. PDA's charity partners, Pharmacist Support also offer a range of options including- Counselling and peer support; Financial support; A listening friend service and Addiction support. Candidates can also access the Wardley Wellbeing Service here. This is a resource to help candidates to prioritise their mental, physical and emotional health through individual and group training. The PDA has also reminded all candidates that there have been some changes made by the GPhC to address problems that occurred in the June 2022 sitting.

The Royal Pharmaceutical Society (RPS) recently announced a valuable addition to their e-library collection: the Maudsley Deprescribing Guidelines, authored by renowned experts Mark Horowitz and David Taylor. Designed to assist pharmacists and clinicians in recognising and appropriately treating withdrawal effects of medications, the guidelines have garnered praise from industry figures like Peter Pratt, National Speciality Advisor for Mental Health Pharmacy and RPS Fellow. This initiative responds to the increasing demand for guidance on safely reducing or discontinuing psychiatric medications, providing comprehensive support for clinicians and patients alike. Drawing on insights from contributors to The Lancet Psychiatry, the handbook offers step-by-step instructions for tapering antidepressants, benzodiazepines, gabapentinoids, and z-drugs, along with troubleshooting strategies.

The Royal Pharmaceutical Society (RPS) and Pharmacy Declares are inviting pharmacy teams from around the world to sign up and commit to taking "bold action" on climate change as mentioned in a climate change charter which was published on Monday (June 13). The charter asks pharmacy teams to commit to understanding how human health and the systems which underpin it are "reliant on the state of our natural environment" and actively explore ways to make pharmacy practice and medicine use more sustainable. It also asks to collaborate and share best practice to improve sustainability in pharmacy and healthcare; demonstrate leadership on sustainability or being a champion for sustainability at work; and assist patients to optimise their medicine use to increase both health outcomes and environmental sustainability. The individuals can also commit to a personal action on climate change of their own choosing. The Charter is being supported by a strong coalition of organisations from across pharmacy including the Centre for Postgraduate Pharmacy Education, the Clinical Pharmacy Association, College of Mental Health Pharmacy and Guild of Healthcare Pharmacists.

Pharmacy professionals to be included as key stakeholders in the implementation, delivery and evaluation of a wide range of genomic services, said the Royal Pharmaceutical Society (RPS). RPS's statement has been developed in collaboration with pharmacy organisations who have co-badged the report, such as the British Oncology Pharmacy Association, the UK Clinical Pharmacy Association, Association of Pharmacy Technicians and the College of Mental Health Pharmacy. It looks at current and future roles for pharmacy professionals in genomic medicine across many aspects of practice such as person-centred care and collaboration, professional practice, education, leadership, management and research. Pharmacists and pharmacy technicians in the UK have already established roles in the application of genomic medicine in some areas of practice, such as antimicrobial stewardship and infectious diseases, and the management of certain genetic conditions, such as cystic fibrosis. The society believes, the current role of pharmacy professionals in genomics can be expanded upon in the future to both lead and support many relevant aspects of genomic implementation. These are described across all healthcare sectors, within the Genome UK strategy produced by the UK Government, and within the implementation plans published in England, Scotland and Wales. Lead for Pharmacogenomics at RPS Sophie Harding said: "Pharmacy professionals are the gatekeepers of medication safety and efficacy across all areas of healthcare. They are skilled at interpreting complex scientific data and use evidence-based medicine to maximise the benefits of treatments for patients, whilst supporting shared decision-making with patients and the multidisciplinary team.

The result of the common registration assessment for pharmacists, held jointly by the General Pharmaceutical Council (GPhC) and Pharmaceutical Society of Northern Ireland (PSNI), have been published with an overall pass rate of 80 per cent. A total of 2,697 candidates sat the registration assessment in four countries on 29 June and 2,147 candidates passed the assessment. This summer's pass rate has fallen to 80 per cent compared with the 82 per cent pass rate for the summer 2021 registration assessment, and the 61 per cent pass rate for the Autumn 2021 registration assessment. GPhC chief executive Duncan Rudkin said: "We would like to congratulate the successful candidates and we look forward to them joining our register and continuing to the next stage of their career. "However, we appreciate that the June registration assessment was a difficult and stressful experience for many - and we are extremely sorry about the problems faced by a number of candidates on the day. "For those who did not pass, there is a guide on our website [PDF 255 KB] outlining all the options that may be available, such as provisional registration and the right to appeal. There are also links to organisations and resources that can provide support with mental health and wellbeing.

NHS England's decision to forgo commissioning puberty suppressing hormones (PSH) for children and young people, citing insufficient evidence of their safety and clinical effectiveness, follows a comprehensive review conducted by the National Institute for Health and Care Excellence (NICE) in 2020. The clinical report underscores that "PSH treatment options will not be part of routine commissioning" for people under the age of 18 in England grappling with gender incongruence or dysphoria. The NHS England review analysed nine observational studies on Gonadotrophin Releasing Hormone Analogues (GnRHa) and found no statistically significant difference in gender dysphoria, mental health, body image, and psychosocial functioning among children and adolescents treated with GnRHa. Duncan Rudkin, chief executive of the General Pharmaceutical Council (GPhC), acknowledged the challenges faced by pharmacy professionals regarding prescriptions for puberty suppressing hormones, stating: